Research programme: antibody-drug conjugates - PDL BioPharma

Drug Profile

Research programme: antibody-drug conjugates - PDL BioPharma

Alternative Names: Anti-TMEFF2 ADC; Anti-TMEFF2-MMAE conjugate; Anti-TMEFF2-monomethyl auristatin E conjugate; Anti-tomoregulin ADC; Anti-tomoregulin-MMAE conjugate; Anti-tomoregulin-monomethyl auristatin E conjugate; Humanised anti-TMEFF2-auristatin E conjugated mAb; Humanised anti-TMEFF2-auristatin E conjugated monoclonal antibody; Humanised anti-tomoregulin-auristatin E conjugated mAb; Humanised anti-tomoregulin-auristatin E conjugated monoclonal antibody; huPr1-vcMMAE; PR1-ADC; Pr1-vc-MMAE

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PDL BioPharma
  • Developer Seattle Genetics
  • Class Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)
  • 16 Aug 2006 This programme is still in active development
  • 09 Jan 2006 Protein Design Labs is now called PDL BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top